2022

1. Sapanisertib plus Fulvestrant in Postmenopausal Women with Estrogen Receptor-Positive/HER2-Negative Advanced Breast Cancer after Progression on Aromatase Inhibitor

   Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 28, Núm. 6, pp. 1107-1116